BALTIMORE, Md. and MONTREAL, July 29, 2024 /PRNewswire/ — Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de Montréal’s affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology’s personalized MRD technology (Haystack MRD™) to evaluate treatment effectiveness in patients with metastatic colorectal cancer (mCRC) with metastases confined to the liver.
This prospective, observational study, Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients (eDetect), will use Haystack MRD to assess circulating tumor DNA (ctDNA) as an early biological marker of treatment response and disease recurrence in patients with mCRC undergoing systemic treatment and liver surgery with curative intent. Haystack MRD is a blood-based liquid biopsy test that measures ctDNA shed into circulation by solid tumors in order to identify residual, recurrent, or resistant cancer, at the earliest possible stage.
“Our collaboration with the CRCHUM presents a valuable opportunity to leverage the performance of our Haystack MRD technology in a population of mCRC patients for whom cure is possible,” said Dan Edelstein, Vice President and General Manager of Haystack Oncology. “Designed for detecting ctDNA with exceptional sensitivity, Haystack MRD is well-suited to measure treatment response in oligometastatic CRC patients to better understand how ctDNA can guide the sequence and intensity of therapy in the future.”
Université de Montréal’s affiliated hospital research centre, the CRCHUM, is one of North America’s leading hospital research centres. Located in the heart of Montreal, the CRCHUM is a major centre for creation, knowledge generation and training.
“mCRC is a challenging disease in need of improved biomarkers to guide optimal patient care,” said Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at the CRCHUM, also principal investigator of the eDetect study. “By teaming up with Haystack, we will be able to understand the best use of the MRD technology to inform treatment decisions. This will guide the design of future interventional trials to assess impact on patient survival.”
Colorectal cancer is the second leading cause of cancer death in Canada and the United States, representing approximately 62,310 related deaths in 2023.1,2 While early-stage CRC can frequently be cured by surgery (with or without adjuvant chemotherapy), mCRC is often treatment-resistant and can be more difficult to address.3
Metastases are the primary cause of colorectal cancer-related mortality, with the liver being the most frequent site for metastasis, followed by the lung. Patients presenting with metastases confined to the liver represent a unique clinical opportunity to pursue surgery with intent to cure. However, even after surgery with no evidence of residual tumor by medical imaging, 80% of patients relapse. A more sensitive diagnostic tool, such as ctDNA, is needed to detect whether residual microscopic cancer cells remain after surgery, to detect relapse earlier than medical imaging so as to treat before the disease burden is too high, and to know as early as possible whether chemotherapy is effective to limit unnecessary use and side effects.
About Haystack OncologyHaystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD™, a next generation tumor-informed approach for the measurement of minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules. Haystack Oncology works with biopharmaceutical companies to accelerate and better inform clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Learn more at haystack mrd.
About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world’s largest databases of deidentified clinical lab results, Quest’s diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
About Université de Montréal’s affiliated hospital research centre, the CRCHUMUniversité de Montréal’s affiliated hospital research centre, the CRCHUM, is one of North America’s leading hospital research centres. Its mission is to improve adult health through a research continuum that includes disciplines such as basic science, clinical research and population health. More than 2,150 people work at the CRCHUM, including nearly 500 researchers and some 650 students and postdoctoral fellows. crchum.com
1 2023 Colorectal Cancer Statistics | Canadian Cancer Society
2 USA National Cancer Institute | Colorectal Cancer — Cancer Stat Facts
3 Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023 Apr;44(4):222-236. doi: 10.1016/j.tips.2023.01.003. Epub 2023 Feb 23. PMID: 36828759; PMCID: PMC10365888.
SOURCE Quest Diagnostics
